Previous European studies suggest NOD2/CARD15 and IL-23R donor or recipient variants are associated with adverse clinical outcomes in allogeneic hematopoietic stem cell transplantation. We re-examined these findings as well as the role of another inflammatory bowel disease (IBD) susceptibility gene (IRGM) on transplant outcomes in 390 US patients and their matched unrelated donors, accrued between 1995-2004. Patients received T-replete grafts using mostly myeloablative conditioning regimens. Multivariate analyses were performed for overall survival, disease-free survival, transplant-related mortality, relapse, and acute and chronic graft-versus-host disease (GVHD). Of 390 pairs, NOD2/CARD15 variant single nucleotide polymorphisms (SNPs) were found in 14% of donors and 17% of recipients. In 3% both donor and recipient had a mutant SNP. 13% of donors and 16% of recipients had variant IL23R SNPs, with 3% having both donor and recipient variants. 23% of both donors and recipients had variant IRGM SNPs. None of the 3 IBD-associated alleles showed a statistically significant association with any adverse clinical outcomes. Our results do not support an association between the 3 IBD-associated SNPs and adverse outcomes following matched unrelated donor hematopoietic cell transplantations in US patients.
INTRODUCTION
Allogeneic hematopoietic stem cell transplant (HSCT) is an important and potentially curative intervention in the management of a range of hematologic malignancies, but the efficacy and outcome of this treatment is frequently limited by its inherent immunologic sequelae. Among the dominant complications of HSCT, graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality, and considerable attention has focused on strategies to limit its development while not completely eliminating the beneficial graft-versus-leukemia effect 1 . These strategies have included allelic HLAmatching, appropriate donor selection, T-cell depletion, and other prophylactic immunosuppressive regimens.
Earlier observations revealed extensive gastrointestinal mucosal damage in patients with GVHD, raising the suggestion that resultant bacterial translocation might play a role in both the initiation and maintenance of a systemic inflammatory response as a result of the conditioning regimen and which could potentially represent a key inciting event in the pathogenesis of GVHD 2 . These observations, coupled with an extensive literature pointing to the role of bacterial flora in the etiology of idiopathic inflammatory bowel disease (IBD), have together reinforced the concept that luminal bacterial communities may represent key elements in the host response to injury 3 . Indeed, genome-wide association studies have identified more than 30 distinct loci linked with susceptibility to Crohn's disease including genes involved in innate host defense 4, 5 6 7 . Accordingly, an emerging consensus suggests that GVHD and IBD, both immune-mediated inflammatory conditions, may share overlapping pathways in their pathogenesis.
Among the many candidate IBD-associated genes, NOD2/CARD15 was initially identified as a susceptibility gene in Crohn's disease with a frequency of 7.7%-9.1% in the healthy U.S. population 8 . NOD2/CARD15 encodes a cytosolic protein that recognizes a bacterial cell wall component, muramyl dipeptide, and results in downstream activation of innate pathways of host defense. Three informative single nucleotide polymorphisms (SNPs) in NOD2/CARD15 have been identified including Leu1007fsinsC, a cytosine insertion that produces a 33 amino acid protein truncation, and two missense mutations Arg702Trp and Gly908Arg (SNPs 8, 12 and 13, respectively) 9, 10 .
The importance of these allelic variants in the pathogenesis of GVHD was suggested by Holler et al, who initially demonstrated that SNPs 8, 12 , and 13 of the NOD2/CARD15 gene in either donor or recipient (from a European cohort) was associated with increased incidence and severity of acute GVHD, increased transplant-related mortality, and reduced survival in HLA-matched sibling transplants. These effects were most pronounced in pairs with the risk variant in both donor and recipient 11 . A follow-up study by the same group demonstrated an increased risk of severe acute GvHD, but not mortality in unrelated donor (URD) transplants. In addition, when broken down by individual polymorphism, SNP 13 was the only significant risk factor 12 . While these findings suggested the importance of NOD2/CARD15 variants in GVHD, other studies have demonstrated conflicting results that failed to confirm these associations [13] [14] [15] . Accordingly, the aim of the current study was to evaluate the impact of NOD2/CARD15 and two other IBD-associated SNPs, on the outcomes of HSCT in a U.S. population. We selected IRGM (immunity-related GTPase family, M) a gene product involved in autophagy and intracellular pathogen clearance, since variations in or near the IRGM locus have been associated with increased susceptibility to Crohn's Disease 16 , and IL23R (interleukin 23 receptor) since variants appear to have a protective role in the development of IBD 17 . In addition, recent findings in adults 18 and, more recently, in children 19 indicated a protective effect of the variant IL23R in donors from the development of GVHD after HSCT. Nevertheless, our findings, fail to show a significant effect (at the p<0.01 level) of variants in these SNPs and the outcomes of HSCT. (Table 1) . GVHD prophylaxis employed combinations of cyclosporine, tacrolimus and methotrexate as detailed in Table 1 . Gut decontamination was not routinely performed, but the prevalence of this practice varies widely and was not systematically recorded in the data collected. Patients and donors were of predominately European American descent, 92.2% and 94.5%, respectively with 6.7% racial/ethnic minorities (Table 1) . Median time of follow-up was 77 months (range 12-149). Approval was obtained from the Washington University Human Studies Committee, and all patients and donors gave their informed and written consent to the NMDP for genetic analysis of their biological samples in accordance with the Declaration of Helsinki.
MATERIALS AND METHODS

Patient populations and treatment regimen
Genotyping of SNPS
DNA was extracted from frozen whole blood samples collected from donors and patients pre-transplant using QIAGEN Blood Kit with Proteinase K. Genomic DNA was isolated using a QIAmp DNA Blood Mini Kit (QIAgen, Germany) following the manufacturer's instructions. Control samples of each genotype, which were confirmed by sequencing, were included in each run. DNA was genotyped for three NOD2/CARD15 SNPs (rs2066844, rs2066845 and rs2066847), two IL23R SNPs (rs11209026 and rs11465804), and two IRGM SNPs (rs4958847 and rs13361189) using Sequenom and/or Taqman SNP Genotyping Assay (PE Applied Biosystems, Foster City, CA, USA). Each reaction was performed in a 96-well plate. The optimized reaction mix of a final volume of 50 µL consisted of Universal Master Mix and the DNA template. The sequence of the primers used is available upon request.
Data Analysis and Statistical Considerations
Individuals heterozygous for at least one of the three NOD2/CARD15 SNPs analyzed (SNPs 8, 12, and 13) were considered variant, whereas individuals lacking these SNPs were considered wild-type. Clinical variables analyzed include CMV status, disease, graft source, GVHD prophylaxis, Karnofsky score, donor and patient age, donor/recipient gender mismatch, myeloablative vs. non-myeloablative conditioning, and year of transplant. Diagnosis for acute or chronic GVHD was based on clinical signs, and/or histopathological findings in biopsies from skin, liver and the gastrointestinal tract. Grading of acute GVHD was performed based on the Glucksberg criteria 20 . Multivariate analyses were performed using Cox proportional hazards regression analysis for overall (OS) and disease free survival (DFS), transplant-related mortality (TRM), relapse, and acute and chronic GVHD, adjusting for the previously mentioned clinical variables. Due to the multiple testing performed within the multivariate analysis, a p-value of less than 0.01 is considered significant. SAS software version 9.1 (SAS Institute, Cary, NC) was used in all analyses.
RESULTS
Patient characteristics
The distribution by age, gender and disease is shown in Table 1 . Most (74%) patients receiving transplants were between the ages of 20 and 50, with the majority (63%) being performed for CML. The majority of patients underwent bone marrow grafting (81%) and 98% of subjects underwent a myeloablative conditioning regimen prior to transplant (Table 1) .
Frequency distribution of NOD2/CARD15, IL-23R, and IRGM variants
NOD2/CARD15 variant SNPs were found in 56 donors (14%) and 67 recipients (17%), with an overall frequency of 16% in this cohort (Figure 1 ). In 44 pairs (11%) the mutation was detected in the donor only, in 55 pairs (14%) the mutation occurred in the recipient only, and in 12 pairs (3%), both donor and recipient had a mutant SNP. The small number of donor/recipient pairs that both had a variant NOD2/CARD15 SNP precludes further analysis to determine statistical significance. Frequencies for individual mutated SNPs were 3% for donors and 3% for recipients for SNP 8; 5% of donors and 5% of recipients for SNP 12, and 6.4% for donors and 9.5% for recipients for SNP 13 ( Table 2 ).
For IL23R, 46 (13%) of donors and 55 (16%) of recipients had variant SNPs (n=353 pairs analyzed, Figure 1 ). In 35 pairs (10%) the mutation occurred in the donor only, in 44 pairs (12%) the mutation occurred in the recipient only, and in 11 pairs (3%) both donor and recipient had variant SNPs (Table 2 ).
For IRGM, variant SNPs were seen in 90 (23%) of donors and 90 (23%) of recipients (n=385 pairs analyzed, Figure 1 ). In 66 pairs (17%) the mutation occurred in the donor only, in 66 pairs (17%) the mutation occurred in the recipient only, and in 24 pairs (6%) both donor and recipient had a mutant SNP, ( Table 2) . Table 3 shows the overall incidence of the endpoints which were analyzed. The overall incidence of 100-day severe acute GVHD (grade III-IV) was 21% (17-25%) and 1-year chronic GVHD was 53% (48-58%). GI GVHD rates at 100 days for stages 2-4 was 14% (11-18%) and for stages 3-4 was 8% (5-11%). These rates and those of other major outcomes were similar to previously published results in a US cohort 21 . In comparison, the overall incidence of severe acute GVHD (grade III-IV) for matched unrelated donor transplants cited in the Holler et al study was higher at 28% 12 . Rates of GI GVHD (grade II-IV) were calculated to be higher in the mixed cohort of unrelated and related donor transplants in the Holler et al study (41 of 169 donor/patient pairs or 24.5%) 11 . In general, the incidence of chronic GVHD in European centers has been reported at 27%-57% 22, 23 .
Incidence of clinical endpoints
None of the 3 IBD-associated alleles showed evidence of a statistically significant association with any of the clinical outcomes at p <0.01 [ Figure 2 ]. In particular there was no association between the three NOD2/CARD15 SNPs (8, 12, or 13) 
03).
Even combining all 3 IBD-associated alleles into one "combination variable" (ie where any mutation in any one of the 3 alleles would be considered variant) failed to demonstrate an association with outcome.
DISCUSSION
Among the target organs for GVHD, tissue injury is most pronounced throughout the gastrointestinal tract, which functions as a reservoir for bacterial communities. These resident bacterial flora interact with the host to generate luminal bacterial products, such as lipopolysaccharide, that then translocate across the bowel and perpetuate both a local and systemic inflammatory response 2 . The role of luminal bacterial contents and host interactions in mediating intestinal injury is further underscored by findings in both animal models as well as earlier clinical studies which each suggested that gut decontamination was associated with decreased incidence of GVHD 13, 24, 25 . The further demonstration that polymorphic variants (including NOD2/CARD15) known to modulate the innate immune response may be informative predictors of adverse outcomes in GVHD prompted us to re-examine this association in a US population with standardized transplant protocols. This was an important objective in view of distinctive practice patterns including the use of T-cell depletion, conditioning regimen, gut decontamination, and HLA-matching, that make those earlier findings from European centers difficult to extrapolate to a US population. Gut decontamination, for example, is not routine practice in the U.S., but its use does vary widely amongst various transplant centers. Our findings, by contrast with those earlier reports, suggest that NOD2/CARD15 variants in either the donor or recipient are not significantly associated with clinical outcomes following HSCT in matched unrelated donor transplants. We also concluded that IL-23R donor genotype, despite previous reports of a protective effect on the occurrence of acute GVHD 19 and improved death rates in remission 18 , had no effect on outcome. We also included another IBD associated genes, IRGM, which has heretofore not been reported in the context of HSCT outcomes. This gene also did not show an association with any clinically significant outcome. These findings bear further discussion in light of conflicting reports involving the association of NOD2/CARD15 and IL-23R SNPs and HSCT outcomes in different populations.
The initial findings of Holler et al suggested a pathogenic role of NOD2/CARD15 variants in the outcomes of HSCT and were based on observations in 169 recipients and their matched donors from two European centers 11 . Those authors reported that NOD2/CARD15 mutations in either the donor or recipient increased the incidence of transplant related mortality and acute GVHD. Furthermore, pairs where NOD2/CARD15 risk alleles were present in both donor and recipient experienced a 1-year TRM of 83% compared to 20% in wild-type pairs (P<0.001). Our study, a retrospective cohort, did not contain sufficient numbers of pairs in which both the donor and recipient had a NOD2/CARD15 mutation and was thus underpowered to perform this particular analysis. A follow-up study by Holler expanded the original cohort of sibling donor transplants (n=78) with an additional 225 donor/recipient pairs from 4 additional European centers. The association of NOD2 mutations and adverse outcomes was again confirmed and the findings suggested that gut decontamination attenuated the effect of NOD2 mutations on TRM 24 . A further study yet again expanded the study cohort and pooled all the related (n=358) and unrelated (n=342) donor recipient pairs to show that there was a weak association with NOD2/CARD15 variants with GVHD, and there was no overall impact on TRM and OS
.
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The implications of those initial reports, namely that NOD2/CARD15 genotyping might have a role in preemptive stratification of risk profiles in patients undergoing HSCT prompted studies at other centers to validate those findings 14, 26 . van der Velden and colleagues used partially T-depleted grafts in sibling donor transplants and found a significant impact of NOD2/CARD15 polymorphisms on severe acute GVHD and TRM rates when both the donor and recipient had a mutation 26 . A separate study in the UK involving 196 unrelated donor transplants for acute leukemia, the majority of which were T-depleted grafts, also confirmed an increased risk of relapse and overall mortality in recipients with NOD2/CARD15 mutations 14 . While these findings support at least some of the earlier conclusions linking NOD2/CARD15 polymorphisms to worse outcomes following transplantation, other work has reported less consistent findings. Studies have revealed, for example, that donor NOD2/CARD15 mutations led to an unexpected reduction in acute GVHD, whereas both donor and recipient NOD2/CARD15 mutations led to the highest incidence of severe GVHD and gut GVHD 13 . Granell and colleagues found an increased risk of relapse and death in patients with NOD2/CARD15 variants undergoing T-cell depleted sibling transplants for acute leukemia with those outcomes being independent of the development of acute or chronic GVHD
22 . Yet another study, involving 198 unrelated and sibling transplants, revealed no association between NOD2/CARD15 variants and negative outcomes following HSCT 15 . Clearly subtle differences in practice patterns in these various centers may account for the variance in the findings, but the findings suggest at the very least there is uncertainty regarding the association between NOD2/CARD15 mutations and the outcomes of HSCT.
In attempting to reconcile our findings with these earlier studies, we can point to some important differences between our study and previous reports. First, the current study group had a lower incidence of NOD2/CARD15 variants, which may have led to our cohort being underpowered to detect a difference in outcome. Among the reasons for the lower mutant frequencies are that our patients were drawn from a more ethnically diverse population, which included 6.7% racial/ethnic minorities. Previous epidemiologic studies have demonstrated that mutations in the NOD2/CARD15 gene are extremely rare outside the Caucasian population 8 . Secondly, our observed rates of GVHD were also lower than earlier studies, which may reflect our exclusion of any donor-recipient mismatched pairs and higher proportion of bone marrow as the stem cell source as opposed to peripheral blood stem cells. Although peripheral blood stem cells are used more commonly today, the inclusion period of this study (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) dates back to when bone marrow was still the more common source of stem cells and the number of bone marrow transplants in our cohort exceeded peripheral blood stem cell transplants until 2003. Future studies will be required to address the outcomes using predominantly or exclusively peripheral blood stem cells. Lastly, it is likely that NOD2/CARD15 effects may be more pronounced if donor T-cells are strongly suppressed as originally suggested 12 and recently reported 26 It is also worth noting that the use of T-replete grafts, unrelated donors, and lack of gut decontamination as employed in the current study are factors that one would typically associate with a higher incidence of GVHD. In particular, given the emerging role of luminal flora in the pathogenesis of IBD 27 one would have predicted a priori that the lack of gut decontamination would if anything exacerbate the incidence of GVHD. However, this was not the case. It is not routine practice in U.S. transplant centers to use gut decontamination as was performed in the majority of the aforementioned studies from European centers, but the exact frequency is unknown and not recorded in the NMDP database.
In designing this study, we selected several IBD markers with a plausible role in GVHD. The findings in regard to IRGM, which has not previously been studied in relationship to HSCT outcomes, have yielded provocative but as yet inconclusive results. Our findings suggest that IRGM variant status did trend towards improved overall survival, diseasefree survival, and transplant-related mortality. Nevertheless, due to the multiple variables examined, we selected a p-value of <0.01 to meet statistical significance and we conclude that further study will be required to confirm and extend these associations. Several other IBD-associated genes have recently been elucidated and these may also merit examination in the future to determine if there is a role for polymorphic variants in the development of GVHD. In this context, it is worth emphasizing that the use of non-HLA genes in association studies of transplant outcome should be interpreted with caution, and in the context of biological plausibility, in order to justify further analysis of a particular inflammatory cytokine. By way of example, mouse genetic studies may serve as an invaluable tool in this regard as the findings from NOD2/CARD15 knockout mice point to a key role in innate intestinal immunity 28 and other recent findings which suggest that genetic deletion of the p19 dimer of IL23 may be protective against GVHD 29 .
In conclusion, due to the lack of any clear association between the studied variant SNPs and outcomes following HSCT, our data do not support the routine use of NOD2/CARD15, IL-23R, or IRGM polymorphism screening in the patient-donor selection process for HSCT. Further studies are needed to determine if these polymorphisms would have an effect in sibling donor transplants, a population not included in this study, or in exclusively peripheral blood stem cell-based transplants in the U.S. I  B  D  -m  a  r  k  e  r  S  N  P   G  r  a  d  e  I  I  -I  V  A  c  u  t  e  G  V  H  D   G  r  a  d  e  I  I  I  -I  V  A  c  u  t  e  G  V  H  D   G  r  a  d  e  I  I  -I  V  G  I  G  V  H  D   G  r  a  d  e  I  I  I  -I  V For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
